Novelties in Dermatology
Omalizumab in the Treatment of Chronic Urticaria
Omalizumab en el tratamiento de la urticaria crónica
L. Francés
, M. Leiva-Salinas, J.F. Silvestre
Autor para correspondencia
Sección de Dermatología, Hospital General Universitario de Alicante, Alicante, España
Leído
13751
Vecesse ha leído el artículo
3775
Total PDF
9976
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 147 | 76 | 223 |
| 2025 5 | 378 | 64 | 442 |
| 2025 4 | 356 | 41 | 397 |
| 2025 3 | 289 | 34 | 323 |
| 2025 2 | 278 | 51 | 329 |
| 2025 1 | 142 | 33 | 175 |
| 2024 12 | 160 | 34 | 194 |
| 2024 11 | 161 | 83 | 244 |
| 2024 10 | 131 | 66 | 197 |
| 2024 9 | 146 | 41 | 187 |
| 2024 8 | 206 | 67 | 273 |
| 2024 7 | 169 | 42 | 211 |
| 2024 6 | 161 | 49 | 210 |
| 2024 5 | 151 | 54 | 205 |
| 2024 4 | 120 | 38 | 158 |
| 2024 3 | 168 | 44 | 212 |
| 2024 2 | 164 | 47 | 211 |
| 2024 1 | 122 | 51 | 173 |
| 2023 12 | 151 | 30 | 181 |
| 2023 11 | 141 | 45 | 186 |
| 2023 10 | 141 | 58 | 199 |
| 2023 9 | 152 | 324 | 476 |
| 2023 8 | 99 | 35 | 134 |
| 2023 7 | 149 | 61 | 210 |
| 2023 6 | 115 | 27 | 142 |
| 2023 5 | 90 | 31 | 121 |
| 2023 4 | 152 | 24 | 176 |
| 2023 3 | 80 | 25 | 105 |
| 2023 2 | 63 | 33 | 96 |
| 2022 1 | 65 | 27 | 92 |
| 2022 12 | 78 | 45 | 123 |
| 2022 11 | 70 | 30 | 100 |
| 2022 10 | 45 | 25 | 70 |
| 2022 9 | 39 | 36 | 75 |
| 2022 8 | 45 | 40 | 85 |
| 2022 7 | 43 | 40 | 83 |
| 2022 6 | 48 | 25 | 73 |
| 2022 5 | 120 | 40 | 160 |
| 2022 4 | 120 | 43 | 163 |
| 2022 3 | 130 | 54 | 184 |
| 2022 2 | 92 | 35 | 127 |
| 2021 1 | 94 | 47 | 141 |
| 2021 12 | 57 | 47 | 104 |
| 2021 11 | 93 | 57 | 150 |
| 2021 10 | 135 | 54 | 189 |
| 2021 9 | 83 | 53 | 136 |
| 2021 8 | 87 | 49 | 136 |
| 2021 7 | 84 | 37 | 121 |
| 2021 6 | 77 | 38 | 115 |
| 2021 5 | 130 | 49 | 179 |
| 2021 4 | 204 | 95 | 299 |
| 2021 3 | 95 | 36 | 131 |
| 2021 2 | 86 | 49 | 135 |
| 2020 1 | 58 | 35 | 93 |
| 2020 12 | 77 | 36 | 113 |
| 2020 11 | 47 | 24 | 71 |
| 2020 10 | 35 | 21 | 56 |
| 2020 9 | 44 | 23 | 67 |
| 2020 8 | 37 | 26 | 63 |
| 2020 7 | 39 | 17 | 56 |
| 2020 6 | 28 | 30 | 58 |
| 2020 5 | 19 | 27 | 46 |
| 2020 4 | 28 | 28 | 56 |
| 2020 3 | 28 | 29 | 57 |
| 2020 2 | 6 | 11 | 17 |
| 2020 1 | 4 | 6 | 10 |
| 2019 12 | 6 | 9 | 15 |
| 2019 11 | 4 | 8 | 12 |
| 2019 10 | 0 | 10 | 10 |
| 2019 9 | 9 | 5 | 14 |
| 2019 8 | 8 | 2 | 10 |
| 2019 7 | 7 | 11 | 18 |
| 2019 6 | 6 | 22 | 28 |
| 2019 5 | 6 | 35 | 41 |
| 2019 4 | 12 | 18 | 30 |
| 2019 3 | 3 | 3 | 6 |
| 2019 2 | 8 | 4 | 12 |
| 2019 1 | 8 | 0 | 8 |
| 2018 12 | 1 | 0 | 1 |
| 2018 11 | 3 | 0 | 3 |
| 2018 10 | 3 | 0 | 3 |
| 2018 9 | 3 | 0 | 3 |
| 2018 3 | 4 | 0 | 4 |
| 2018 2 | 70 | 4 | 74 |
| 2018 1 | 79 | 8 | 87 |
| 2017 12 | 89 | 10 | 99 |
| 2017 11 | 54 | 5 | 59 |
| 2017 10 | 81 | 7 | 88 |
| 2017 9 | 54 | 14 | 68 |
| 2017 8 | 57 | 11 | 68 |
| 2017 7 | 42 | 15 | 57 |
| 2017 6 | 61 | 22 | 83 |
| 2017 5 | 39 | 19 | 58 |
| 2017 4 | 59 | 11 | 70 |
| 2017 3 | 36 | 49 | 85 |
| 2017 2 | 87 | 9 | 96 |
| 2016 1 | 49 | 17 | 66 |
| 2016 12 | 70 | 4 | 74 |
| 2016 11 | 99 | 24 | 123 |
| 2016 10 | 125 | 25 | 150 |
| 2016 9 | 167 | 26 | 193 |
| 2016 8 | 77 | 13 | 90 |
| 2016 7 | 41 | 13 | 54 |
| 2016 6 | 7 | 13 | 20 |
| 2016 5 | 18 | 25 | 43 |
| 2016 4 | 9 | 12 | 21 |
| 2016 3 | 4 | 8 | 12 |
| 2016 2 | 4 | 5 | 9 |
| 2015 1 | 7 | 3 | 10 |
| 2015 12 | 9 | 4 | 13 |
| 2015 11 | 6 | 20 | 26 |
| 2015 10 | 8 | 6 | 14 |
| 2015 9 | 9 | 5 | 14 |
| 2015 8 | 6 | 4 | 10 |
| 2015 7 | 75 | 1 | 76 |
| 2015 6 | 88 | 10 | 98 |
| 2015 5 | 74 | 17 | 91 |
| 2015 4 | 63 | 19 | 82 |
| 2015 3 | 90 | 11 | 101 |
| 2015 2 | 68 | 5 | 73 |
| 2015 1 | 42 | 5 | 47 |
| 2014 12 | 42 | 6 | 48 |
| 2014 11 | 59 | 14 | 73 |
| 2014 10 | 59 | 5 | 64 |
| 2014 9 | 42 | 16 | 58 |
| 2014 8 | 32 | 24 | 56 |
| 2014 7 | 32 | 18 | 50 |
| 2014 6 | 46 | 19 | 65 |
| 2014 5 | 65 | 17 | 82 |
| 2014 4 | 49 | 10 | 59 |
| 2014 3 | 35 | 22 | 57 |
| 2014 2 | 40 | 36 | 76 |
| 2014 1 | 9 | 10 | 19 |
Mostrar todo
